These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 38343204)

  • 1. Lessons learned from COVID-19, H1N1, and routine vaccine pharmacovigilance in the United States: a path to a more robust vaccine safety program.
    Salmon DA; Chen RT; Black S; Sharfstein J
    Expert Opin Drug Saf; 2024 Feb; 23(2):161-175. PubMed ID: 38343204
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of 'SAEFVIC', A Pharmacovigilance Surveillance Scheme for the Spontaneous Reporting of Adverse Events Following Immunisation in Victoria, Australia.
    Clothier HJ; Crawford NW; Russell M; Kelly H; Buttery JP
    Drug Saf; 2017 Jun; 40(6):483-495. PubMed ID: 28342074
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Challenges in evaluating post-licensure vaccine safety: observations from the Centers for Disease Control and Prevention.
    Moro PL; Haber P; McNeil MM
    Expert Rev Vaccines; 2019 Oct; 18(10):1091-1101. PubMed ID: 31580725
    [No Abstract]   [Full Text] [Related]  

  • 4. Imprecision in vaccine adverse event reporting and a methodological analysis of reporting systems to improve pharmacovigilance and public health.
    Inokuma Y; Kneller R
    Eur J Clin Pharmacol; 2023 Jul; 79(7):989-1002. PubMed ID: 37249640
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaccine Safety and Surveillance for Adverse Events Following Immunization (AEFI) in India.
    Joshi J; Das MK; Polpakara D; Aneja S; Agarwal M; Arora NK
    Indian J Pediatr; 2018 Feb; 85(2):139-148. PubMed ID: 29170922
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Leveraging COVID-19 Vaccine Safety Monitoring in Ethiopia and Pakistan to Enhance System-Wide Safety Surveillance.
    Hagos AA; Sahile Z; Ahmed W; Phanouvong S
    Glob Health Sci Pract; 2024 Feb; 12(Suppl 1):. PubMed ID: 38216210
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A scoping review of active, participant centred, digital adverse events following immunization (AEFI) surveillance of WHO approved COVID-19 vaccines: A Canadian immunization Research Network study.
    Serhan M; Psihogios A; Kabir N; Bota AB; Mithani SS; Smith DP; Zhu DT; Greyson D; Wilson S; Fell D; Top KA; Bettinger JA; Wilson K
    Hum Vaccin Immunother; 2024 Dec; 20(1):2293550. PubMed ID: 38374618
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and feasibility of SMS m-Health for the detection of adverse events following immunisation (AEFIs) in resource-limited setting-The Zimbabwe stimulated telephone assisted rapid safety surveillance (Zm-STARSS) randomised control trial.
    Nyambayo PPM; Gold MS; Mehta UC; Clarke S; Manyevere R; Chirinda L; Zifamba EN; Nyamandi T
    Vaccine; 2023 Oct; 41(45):6700-6709. PubMed ID: 37805357
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vaccine pharmacovigilance in India: Current context and future perspective.
    Meher BR
    Indian J Pharmacol; 2019; 51(4):243-247. PubMed ID: 31571710
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vaccine safety in Australia during the COVID-19 pandemic: Lessons learned on the frontline.
    Laemmle-Ruff I; Lewis G; Clothier HJ; Dimaguila GL; Wolthuizen M; Buttery J; Crawford NW
    Front Public Health; 2022; 10():1053637. PubMed ID: 36408022
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adverse events following immunization (AEFI) with the novel influenza a (H1N1) 2009 vaccine: findings from the national registry of all vaccine recipients and AEFI and the passive surveillance system in South Korea.
    Kim JH; Cho HY; Hennessey KA; Lee HJ; Bae GR; Kim HC
    Jpn J Infect Dis; 2012; 65(2):99-104. PubMed ID: 22446114
    [TBL] [Abstract][Full Text] [Related]  

  • 12. COVID-19 mRNA Vaccines: A Retrospective Observational Pharmacovigilance Study.
    Ferrara F; Mancaniello C; Varriale A; Sorrentino S; Zovi A; Nava E; Trama U; Boccellino M; Vitiello A
    Clin Drug Investig; 2022 Dec; 42(12):1065-1074. PubMed ID: 36274082
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Surveillance for adverse events following immunization from 2008 to 2011 in Zhejiang Province, China.
    Hu Y; Li Q; Lin L; Chen E; Chen Y; Qi X
    Clin Vaccine Immunol; 2013 Feb; 20(2):211-7. PubMed ID: 23239804
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Capillary leak syndrome following COVID-19 vaccination: Data from the European pharmacovigilance database Eudravigilance.
    Ruggiero R; Balzano N; Di Napoli R; Mascolo A; Berrino PM; Rafaniello C; Sportiello L; Rossi F; Capuano A
    Front Immunol; 2022; 13():956825. PubMed ID: 36177033
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical assessment of serious adverse events in children receiving 2009 H1N1 vaccination.
    Pahud BA; Williams SE; Dekker CL; Halsey N; Larussa P; Baxter RP; Klein NP; Marchant CD; Sparks RC; Jakob K; Aukes L; Swope S; Barnett E; Lewis P; Berger M; Dreskin SC; Donofrio PD; Sejvar JJ; Slade BA; Gidudu J; Vellozzi C; Edwards KM
    Pediatr Infect Dis J; 2013 Feb; 32(2):163-8. PubMed ID: 23334340
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A scoping review of active, participant-centred, digital adverse events following immunization (AEFI) surveillance: A Canadian immunization research network study.
    Psihogios A; Brianne Bota A; Mithani SS; Greyson D; Zhu DT; Fung SG; Wilson SE; Fell DB; Top KA; Bettinger JA; Wilson K
    Vaccine; 2022 Jul; 40(31):4065-4080. PubMed ID: 35680501
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Best practice implementation on reporting of coronavirus disease 2019 vaccine adverse events following immunization in Uasin Gishu County, Kenya.
    Amdany H; Koech B
    JBI Evid Implement; 2023 Jun; 21(2):146-155. PubMed ID: 36545897
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Surveillance for adverse events following immunization (AEFI) for 7 years using a computerised vaccination system.
    Alguacil-Ramos AM; Muelas-Tirado J; Garrigues-Pelufo TM; Portero-Alonso A; Diez-Domingo J; Pastor-Villalba E; Lluch-Rodrigo JA
    Public Health; 2016 Jun; 135():66-74. PubMed ID: 26976484
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Capacity for a global vaccine safety system: the perspective of national regulatory authorities.
    Graham JE; Borda-Rodriguez A; Huzair F; Zinck E
    Vaccine; 2012 Jul; 30(33):4953-9. PubMed ID: 22658930
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Unveiling vaccine safety: a narrative review of pharmacovigilance in India's COVID-19 vaccination.
    Hegde M; Raj S; Tikadar D; Nyamagoud SB
    Monaldi Arch Chest Dis; 2023 Dec; ():. PubMed ID: 38037892
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.